Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Noam PondéDominique Agbor-TarhLissandra Dal LagoLarissa A KordeFlorentine HilbersChristian JackischOlena WernerRichard D GelberAminah JatoiAmylou C DueckAlvaro Moreno-AspitiaChristos SotiriouEvandro de AzambujaMartine Piccart

Published in: Breast cancer research and treatment (2020)

Trastuzumab plus lapatinib was significantly more toxic among older patients and had worse treatment completion. Trastuzumab was generally well tolerated.

Keyphrases

metastatic breast cancer
epidermal growth factor receptor
clinical trial
positive breast cancer
open label
oxidative stress
phase iii
study protocol
big data
randomized controlled trial
phase ii